8.83
0.09 (1.03%)
Previous Close | 8.74 |
Open | 9.00 |
Volume | 445,610 |
Avg. Volume (3M) | 533,777 |
Market Cap | 533,951,872 |
Price / Earnings (Forward) | 21.14 |
Price / Sales | 1.58 |
Price / Book | 1.38 |
52 Weeks Range | |
Earnings Date | 31 Oct 2024 - 4 Nov 2024 |
Profit Margin | -28.87% |
Operating Margin (TTM) | -15.94% |
Diluted EPS (TTM) | -1.49 |
Quarterly Revenue Growth (YOY) | 3.70% |
Total Debt/Equity (MRQ) | 69.66% |
Current Ratio (MRQ) | 1.18 |
Operating Cash Flow (TTM) | -4.05 M |
Levered Free Cash Flow (TTM) | 27.76 M |
Return on Assets (TTM) | -6.58% |
Return on Equity (TTM) | -23.15% |
Market Trend
Short Term | Medium Term | ||
Industry | Health Information Services (US) | Mixed | Bearish |
Health Information Services (Global) | Mixed | Bearish | |
Stock | Health Catalyst, Inc | Bullish | Bullish |
Stockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 5.0 |
Average | 1.75 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings. |
|
Sector | Healthcare |
Industry | Health Information Services |
Investment Style | Small Value |
% Held by Insiders | 2.82% |
% Held by Institutions | 89.42% |
Ownership
Name | Date | Shares Held |
---|---|---|
Daventry Group, Lp | 30 Jun 2024 | 2,247,053 |
Nepsis Inc. | 30 Jun 2024 | 1,253,080 |
52 Weeks Range | ||
Price Target Range | ||
High | 16.00 (Cantor Fitzgerald, 81.20%) | Buy |
Median | 11.00 (24.58%) | |
Low | 7.00 (Stephens & Co., -20.73%) | Hold |
Average | 11.40 (29.11%) | |
Total | 4 Buy, 1 Hold | |
Avg. Price @ Call | 7.56 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Evercore ISI Group | 08 Oct 2024 | 10.00 (13.25%) | Buy | 7.83 |
Cantor Fitzgerald | 04 Oct 2024 | 16.00 (81.20%) | Buy | 7.70 |
20 Sep 2024 | 16.00 (81.20%) | Buy | 8.69 | |
JP Morgan | 04 Sep 2024 | 13.00 (47.23%) | Buy | 7.54 |
Piper Sandler | 26 Aug 2024 | 11.00 (24.58%) | Buy | 7.16 |
Stephens & Co. | 08 Aug 2024 | 7.00 (-20.72%) | Hold | 7.55 |
No data within this time range.
Date | Type | Details |
---|---|---|
27 Aug 2024 | Announcement | WISHIN Expands Relationship with Health Catalyst, Signing Multi-Year Partnership to Migrate to Ninja Universe™ Suite |
27 Aug 2024 | Announcement | Health Catalyst to Participate in Upcoming Investor Conferences |
08 Aug 2024 | Announcement | Health Catalyst and South Dakota Health Link Expand Partnership to Improve the Quality and Effectiveness of Healthcare in the Midwest |
08 Aug 2024 | Announcement | Health Catalyst Announces Partnership Expansion with Western U.S.'s Largest Health Information Exchange, Contexture |
08 Aug 2024 | Announcement | Health Catalyst Finalizes Acquisition of Leading Care Management Company, Lumeon |
07 Aug 2024 | Announcement | Health Catalyst Reports Second Quarter 2024 Results |
24 Jul 2024 | Announcement | Health Catalyst to Announce Second Quarter 2024 Operating Results and Host Conference Call on Wednesday, August 7, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |